Ardsley Advisory Partners’s Bristol-Myers Squibb BMY Stock Holding History

Ardsley Advisory Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-80,500	Closed	-$4.73M	–	150
2020 Q2	$4.73M	Buy	+80,500	New	+$4.81M	1.01%	29
2019 Q3	–	Sell	-8,500	Closed	-$385K	–	140
2019 Q2	$385K	Sell	8,500 -97,500	-92%	-$4.54M	0.06%	106
2019 Q1	$5.06M	Buy	+106,000	New	+$5.28M	0.97%	32

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Ardsley Advisory Partners's BMY Position: Q3 2020 in Review

Ardsley Advisory Partners sold out of Bristol-Myers Squibb (BMY) in Q3 2020, closing a stake of 80,500 shares — an estimated $4.73M sold.

Ardsley Advisory Partners first reported a position in BMY in Q1 2019 and held it in 3 quarters. The position peaked at $5.06M in Q1 2019. 2,214 funds tracked by Wall St. Rank hold BMY as of Q3 2020.

Ardsley Advisory Partners reported no remaining Bristol-Myers Squibb position as of Q3 2020 after selling out during the quarter.
Ardsley Advisory Partners sold 80,500 Bristol-Myers Squibb shares in Q3 2020, an estimated $4.73M.
Ardsley Advisory Partners first reported a position in Bristol-Myers Squibb in Q1 2019 and held it in 3 quarters.
Ardsley Advisory Partners's Bristol-Myers Squibb position peaked at $5.06M in Q1 2019.
2,214 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2020.

Based on Ardsley Advisory Partners's 13F filing for Q3 2020, filed 13 Nov 2020.